CancerVax

redefining
immunotherapy

Pre-clinical. We’re developing cutting edge immunotherapy cancer treatments that use the body’s immune system to fight cancer.

Universal Cancer Vaccine

Universal Cancer Vaccine

We are developing a Universal Cancer Vaccine (UCV) that will use the body’s own immune system to target and eliminate cancer cells. The UCV will use cutting edge bioengineering and molecular technologies to uniquely detect, mark and kill only cancer cells. By forcing cancer cells to express a unique marker that healthy cells do not have, custom antibody drugs and the body's immune system can target and destroy them with precision. Additionally, we intend to make cancer cells look like common diseases so that the body’s immune system can easily destroy them. We have filed a patent application for the UCV and are working with UCLA to develop the platform, which may be administered as a one or two-shot treatment.

syringe

Ewing Sarcoma

Ewing Sarcoma

We are developing a disease-specific immunotherapy targeted at treating Ewing Sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults and for which there is no current FDA approved treatment for recurrence.

We have entered into a sponsored research agreement with the University of California at Los Angeles (UCLA) to develop effective immunotherapies, such as CAR T-cell and monoclonal antibodies, for Ewing Sarcoma. We have the exclusive right to negotiate and license any resulting intellectual property and have also entered into a Letter of Intent with UCLA to negotiate a license for a pre-existing patent application. UCLA is a top-ranked university known for its cancer research and medical school.

syringe

World-class researchers and scientists.

Our team of dedicated scientists is on the cutting edge of cancer research. From the lab to the clinic, we are committed to finding new and better ways to prevent and treat cancer.

80

Years of collective
experience

health
Steven J. Jonas, MD/PHD

Principal Investigator

Dr. Jonas is a UCLA physician-scientist specializing in pediatric hematology/oncology. He received a bachelor’s degree in materials science & engineering and a master’s degree in biomedical engineering prior to starting his medical training to pursue his M.D. and Ph.D. degrees at UCLA through its NIH-supported Medical Scientist Training Program. He leads a multidisciplinary research team that targets the development and application of new nanotechnologies and methods to support the childhood cancer and regenerative medicine communities in accelerating the discovery of innovative gene therapy approaches.

Satiro de oliveira, MD

Principal Investigator

Watch Interview

Dr. De Oliveira is a board-certified pediatrician and board-certified pediatric hematology/oncologist. He received his medical degree in Brazil and completed his pediatric residency at Woodhull Medical and Mental Health Center in New York and his pediatric hematology/oncology fellowship at the Children’s Hospital Lost Angeles. His clinical focus is on pediatric oncology and gene therapies and his research focus is on cancer immunotherapy and biology of stem cell transplantation.

Christopher Seet, MD/phd

Principal Investigator

Dr. Seet is a hematologist and oncologist subspecializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation, cellular therapy and clinical trials of novel therapeutics. He received a undergraduate degree in Biological Science at the University of Chicago, a medical degree at the University of Sydney, Australia and PhD in Cellular and Molecular Pathology at UCLA. His research focuses on human T cell and dendritic cell tumor immunology, and the development of engineered stem cell-based approaches to cancer therapy.

Noah Federman, MD

Principal Investigator

Dr. Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA. He specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. He received a medical degree from the Icahn School of Medicine at Mount Sinai and completed his residency and fellowship at UCLA.

Christopher Denny, MD

Project Advisor

Dr. Denny has served as a physician at UCLA for over 3 decades primarily focused on pediatric oncology. He has trained and mentored some of UCLA’s best and brightest scientists and doctors in the field. Dr. Denny received a bachelor’s degree from University of Pennsylvania and a medical degree from the University of Pennsylvania School of Medicine. He completed his residency at the Children’s National Medical Center and fellowship at the National Institutes of Health Clinical Center. Most of Dr. Denny’s academic success has come through applying basic molecular biology tools to seek molecular mechanisms for what he witnesses when treating pediatric hematology/oncology patients.

Cancervax

Podcast

CancerVAX Podcast - Dr. Dinesh Patel

CancerVAX Podcast - Stephen Diamond

CancerVax Podcast - Dr. Satiro De Oliveira

CancerVax Podcast - Ryan looper

News Highlights

May 17, 2023

Biotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with CancerVAX CEO Ryan Davies

Lehi, UT – May 17, 2023 – CancerVAX, developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today reported that the Company’s CEO, Ryan Davies

April 20, 2023

Former Pfizer Legal Counsel Discusses Gene Therapy with CancerVAX CEO Ryan Davies

Stephen Diamond, Senior Vice President, General Counsel, and Secretary of Freeline, discussed his unique path from the legal and business worlds to gene therapy and next-generation therapeutics.

April 12, 2023

CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist

Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy

April 3, 2023

CancerVAX Lands Byron Elton

Experienced business executive to help establish the Company as a significant force in the field of cancer research